logo
New Brain Interface Interprets Inner Monologues With Startling Accuracy

New Brain Interface Interprets Inner Monologues With Startling Accuracy

Gizmodoa day ago
Scientists can now decipher brain activity related to the silent inner monologue in people's heads with up to 74% accuracy, according to a new study.
In new research published today in Cell, scientists from Stanford University decoded imagined words from four participants with severe paralysis due to ALS or brainstem stroke. Aside from being absolutely wild, the findings could help people who are unable to speak communicate more easily using brain-computer interfaces (BCIs), the researchers say.
'This is the first time we've managed to understand what brain activity looks like when you just think about speaking,' lead author Erin Kunz, a graduate student in electrical engineering at Stanford University, said in a statement. 'For people with severe speech and motor impairments, BCIs capable of decoding inner speech could help them communicate much more easily and more naturally.'
Previously, scientists have managed to decode attempted speech using BCIs. When people physically attempt to speak out loud by engaging the muscles related to speech, these technologies can interpret the resulting brain activity and type out what they're trying to say. But while effective, the current methods of BCI-assisted communication can still be exhausting for people with limited muscle control. The new study is the first to directly take on inner speech.
To do so, the researchers recorded activity in the motor cortex—the region responsible for controlling voluntary movements, including speech—using microelectrodes implanted in the motor cortex of the four participants.
The researchers found that attempted and imagined speech activate similar, though not identical, patterns of brain activity. They trained an AI model to interpret these imagined speech signals, decoding sentences from a vocabulary of up to 125,000 words with as much as 74% accuracy. In some cases, the system even picked up unprompted inner thoughts, like numbers participants silently counted during a task.
For people who want to use the new technology but don't always want their inner thoughts on full blast, the team added a password-controlled mechanism that prevented the BCI from decoding inner speech unless the participants thought of a password ('chitty chitty bang bang' in this case). The system recognized the password with more than 98% accuracy.
While 74% accuracy is high, the current technology still makes a substantial amount of errors. But the researchers are hopeful that soon, more sensitive recording devices and better algorithms could boost their performance even more.
'The future of BCIs is bright,' Frank Willett, assistant professor in the department of neurosurgery at Stanford and the study's lead author, said in a statement. 'This work gives real hope that speech BCIs can one day restore communication that is as fluent, natural, and comfortable as conversational speech.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

HIMS: Hims & Hers Shares Sink After FTC Probe Details Emerge
HIMS: Hims & Hers Shares Sink After FTC Probe Details Emerge

Yahoo

time4 minutes ago

  • Yahoo

HIMS: Hims & Hers Shares Sink After FTC Probe Details Emerge

Aug 15 - Hims & Hers Health (NYSE:HIMS) slipped about 3% in early trading on Friday after Bloomberg published fresh details about a Federal Trade Commission probe into the company's business practices. The report says the FTC opened an inquiry following consumer complaints that Hims & Hers makes it hard for customers to cancel subscriptions and questions the company's advertising practices. Warning! GuruFocus has detected 4 Warning Sign with HIMS. Hims & Hers first told investors about a regulatory review in July 2024, but Bloomberg's report adds new color on what regulators are investigating. According to people familiar with the matter, the agency looks at cancellation flows, disclosure language, and whether marketing crosses legal lines. The company hasn't released a new statement tied to the Bloomberg story. For investors, the short-term hit reflects the subscription model's vulnerability: when regulators probe cancellation or billing, churn can rise and trust can fall. Analysts will watch complaint volumes, any formal FTC subpoenas, and whether the firm needs to change its renewal mechanics or face penalties. Until that clarity arrives, expect volatility around HIMS shares as traders price regulatory risk into the stock. Based on the one year price targets offered by 13 analysts, the average target price for Hims & Hers Health Inc is $51.22 with a high estimate of $85.00 and a low estimate of $28.00. The average target implies a upside of +8.67% from the current price of $47.13. Based on GuruFocus estimates, the estimated GF Value for Hims & Hers Health Inc in one year is $36.25, suggesting a downside of -23.09% from the current price of $47.13. Gf value is Gurufocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. For deeper insights, visit the forecast page. This article first appeared on GuruFocus. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Philippe Laffont Loads Up on Oracle, ARM--Cuts AMD, Alibaba, Eli Lilly Stakes
Philippe Laffont Loads Up on Oracle, ARM--Cuts AMD, Alibaba, Eli Lilly Stakes

Yahoo

time4 minutes ago

  • Yahoo

Philippe Laffont Loads Up on Oracle, ARM--Cuts AMD, Alibaba, Eli Lilly Stakes

Aug 15 - Philippe Laffont (Trades, Portfolio)'s Coatue shook up its Q2 portfolio, loading into Oracle (ORCL) and ARM (NASDAQ:ARM) while exiting Super Micro (NASDAQ:SMCI) and Monolithic Power (MPWR). The firm bought roughly 3.86 million Oracle shares (about $843.3M) and 4.63 million ARM shares ($749.4M), according to its latest 13F filing, signaling renewed conviction in large-cap cloud and chip plays. Warning! GuruFocus has detected 3 Warning Sign with SMCI. Coatue also increased its stake in CoreWeave (NASDAQ:CRWV) to about 17.8M shares (~$2.9B) and added to positions in Broadcom (AVG) and Nvidia (NASDAQ:NVDA), reflecting a clear tilt toward AI infrastructure. At the same time the hedge fund trimmed holdings in Alibaba (NYSE:BABA), AMD (NASDAQ:AMD) and Eli Lilly (NYSE:LLY), and sold out of Monolithic Power and Super Micro. The moves indicate a change in strategy: strengthen names sensitive to AI compute and cloud capacity and reduce cyclical or less strategic exposure. For investors, the swaps of Coatue are of importance since their bet of more than $0.8B on Oracle reflects its conviction on cloud and software momentum. See what happens to the rest of the large funds; action across the AI related names can exaggerate moves, either upwards when new demand shines through or down when the mood swings. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Berkshire Hathaway Takes $1.6 Billion Stake in UnitedHealth
Berkshire Hathaway Takes $1.6 Billion Stake in UnitedHealth

Yahoo

time4 minutes ago

  • Yahoo

Berkshire Hathaway Takes $1.6 Billion Stake in UnitedHealth

Berkshire Hathaway (BRK.A, Financials) acquired more than 5 million shares of UnitedHealth (UNH, Financials) last quarter, a stake worth about $1.6 billion at the end of June, according to a regulatory filing Thursday. The holding ranks as the conglomerate's 18th largest position, behind Amazon and Constellation Brands, VerityData reported. Warning! GuruFocus has detected 5 Warning Sign with UNH. UnitedHealth shares rose 6% in extended trading following the disclosure. The stock had fallen nearly 50% this year before the filing. The health insurer, under Justice Department investigation for Medicare billing practices, withdrew its earnings guidance in May and later issued a 2025 outlook that missed Wall Street estimates. Chief Executive Andrew Witty stepped down earlier this year. Berkshire's equity portfolio was valued at about $300 billion at the end of June. Buffett will retire as CEO at year-end, with Vice Chairman Greg Abel set to take over and manage capital allocation decisions. This article first appeared on GuruFocus. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store